← All Clearside Biomedical, INC filings

Clearside Biomedical, INC DEF 14A proxy statements

Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.

NASDAQ
CLSD
Clearside Biomedical, INC
DEF: Clearside Biomedical Seeks Reverse Stock Split Approval
Clearside Biomedical, Inc. will hold a Special Meeting to approve a reverse stock split to regain Nasdaq listing compliance.
NASDAQ
CLSD
Clearside Biomedical, INC
DEFA14A: Clearside Biomedical Seeks Stockholder Approval for Increased Share Authorization and Executive Compensation
Clearside Biomedical is holding its annual stockholder meeting on May 30, 2025, to vote on key proposals including the election of directors, executive compensation, auditor ratification, and an increase in authorized common stock.
NASDAQ
CLSD
Clearside Biomedical, INC
DEF: Clearside Biomedical Seeks Stockholder Approval for Increased Share Authorization and Executive Compensation
Clearside Biomedical's proxy statement outlines proposals for the 2025 annual meeting, including director elections, executive compensation approval, auditor ratification, and an increase in authorized common stock.
NASDAQ
CLSD
Clearside Biomedical, INC
DEFA14A: Clearside Biomedical Sets Date for Annual Stockholders Meeting
Clearside Biomedical will hold its annual stockholders meeting on June 20, 2024, to elect directors, approve executive compensation, and ratify the selection of Ernst & Young LLP as independent auditors.
NASDAQ
CLSD
Clearside Biomedical, INC
DEF 14A: Clearside Biomedical Sets Date for Annual Stockholder Meeting, Highlights Progress in Suprachoroidal Delivery
Clearside Biomedical's proxy statement highlights the company's progress in suprachoroidal drug delivery and upcoming data readout for its CLS-AX wet AMD program.